Circio Holding ASA (CRNA) - Total Assets
Based on the latest financial reports, Circio Holding ASA (CRNA) holds total assets worth Nkr10.76 Million NOK (≈ $1.13 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Circio Holding ASA (CRNA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Circio Holding ASA - Total Assets Trend (2020–2025)
This chart illustrates how Circio Holding ASA's total assets have evolved over time, based on quarterly financial data. See CRNA net assets for net asset value and shareholders' equity analysis.
Circio Holding ASA - Asset Composition Analysis
Current Asset Composition (December 2025)
Circio Holding ASA's total assets of Nkr10.76 Million consist of 98.4% current assets and 1.6% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 56.2% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Circio Holding ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Circio Holding ASA (CRNA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Circio Holding ASA's current assets represent 98.4% of total assets in 2025, an increase from 24.4% in 2020.
- Cash Position: Cash and equivalents constituted 56.2% of total assets in 2025, up from 0.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 74.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Circio Holding ASA Competitors by Total Assets
Key competitors of Circio Holding ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Circio Holding ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.46 | 0.63 | 3.14 |
| Quick Ratio | 0.46 | 0.63 | 3.14 |
| Cash Ratio | 0.00 | 0.53 | 2.88 |
| Working Capital | Nkr-12.67 Million | Nkr-12.70 Million | Nkr93.53 Million |
Circio Holding ASA - Advanced Valuation Insights
This section examines the relationship between Circio Holding ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.42 |
| Latest Market Cap to Assets Ratio | 19.08 |
| Asset Growth Rate (YoY) | -50.7% |
| Total Assets | Nkr10.76 Million |
| Market Capitalization | $205.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Circio Holding ASA's assets at a significant premium (19.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Circio Holding ASA's assets decreased by 50.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Circio Holding ASA (2020–2025)
The table below shows the annual total assets of Circio Holding ASA from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr10.76 Million ≈ $1.13 Million |
-50.73% |
| 2024-12-31 | Nkr21.83 Million ≈ $2.30 Million |
-15.10% |
| 2023-12-31 | Nkr25.71 Million ≈ $2.71 Million |
-74.39% |
| 2022-12-31 | Nkr100.41 Million ≈ $10.57 Million |
-82.24% |
| 2021-12-31 | Nkr565.27 Million ≈ $59.48 Million |
+8.55% |
| 2020-12-31 | Nkr520.74 Million ≈ $54.80 Million |
-- |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a … Read more